肥胖与头颈部鳞状细胞癌免疫检查点抑制剂治疗后的生存
这项基于TriNetX数据库的回顾性人群队列研究纳入166例接受免疫检查点抑制剂(ICI)治疗的头颈部鳞状细胞癌(HNSCC)患者,按倾向性评分匹配后比较肥胖BMI(≥30.0)与正常BMI(20.0-24.9)者的生存与功能结局。肥胖BMI与6个月、3年、5年总生存改善相关,并与胃造瘘管和气管套管依赖风险降低相关,吞咽困难和免疫相关不良事件无差异。
要点
- 肥胖BMI组较正常BMI组6个月、3年、5年总生存改善(HR分别为0.54、0.56、0.62)。
- 肥胖BMI组胃造瘘管依赖风险在6个月、1年、3年、5年均降低(OR 0.41、0.41、0.35、0.34)。
- 肥胖BMI组气管套管依赖风险在1年、3年、5年降低(OR 0.52、0.45、0.45)。
核心结论
- 在接受ICI治疗的HNSCC患者中,肥胖与6个月、3年、5年总生存改善相关。
- 肥胖与胃造瘘管和气管套管依赖减少相关。
- 需要进一步研究以理解这些发现的机制。
研究设计与样本
- 回顾性人群队列研究,使用TriNetX全球协作网络数据库。
- 纳入2012年1月1日至2023年12月31日接受ICI治疗的HNSCC患者。
- 经倾向性评分匹配后共166例,正常BMI(20.0-24.9)83例与肥胖BMI(≥30.0)83例。
主要发现
- 肥胖BMI组较正常BMI组总生存改善:6个月HR 0.54(95%CI 0.31-0.96),3年HR 0.56(95%CI 0.38-0.83),5年HR 0.62(95%CI 0.44-0.86)。
- 肥胖BMI组较正常BMI组胃造瘘管依赖风险降低:6个月OR 0.41(95%CI 0.21-0.80),1年OR 0.41(95%CI 0.21-0.78),3年OR 0.35(95%CI 0.18-0.65),5年OR 0.34(95%CI 0.18-0.65)。
- 肥胖BMI组较正常BMI组气管套管依赖风险降低:1年OR 0.52(95%CI 0.28-0.90),3年OR 0.45(95%CI 0.45-0.90),5年OR 0.45(95%CI 0.45-0.90)。
- 各时间点吞咽困难和免疫相关不良事件发生率在两组间无差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要进一步研究以理解这些发现的机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: For patients treated with immune checkpoint inhibitors (ICIs), recent data suggest that obesity has a beneficial effect on survival outcomes in various cancer types. Reports on this association in head and neck cancer are limited. OBJECTIVES: To compare overall survival (OS) to 5 years and functional outcomes in patients with head and neck squamous cell carcinoma (HNSCC) treated with ICIs based on pretreatment body mass index (BMI). DESIGN, SETTING, AND PARTICIPANTS: This retrospective population-based cohort study used data obtained from the TriNetX Global Collaborative Network database to identify patients with HNSCC who received ICI treatment between January 1, 2012, and December 31, 2023, resulting in a total of 166 patients (83 with BMI of 20.0-24.9 [normal BMI] and 83 with BMI of ≥30.0 [obesity BMI]) after propensity score matching (PSM) for pretreatment medical comorbidities and oncologic staging. EXPOSURE: Normal BMI vs obesity BMI. MAIN OUTCOMES AND MEASURES: Overall survival and functional outcomes (dysphagia, tracheostomy dependence, and gastrostomy tube dependence) were measured to 5 years after ICI treatment and compared between patients with obesity BMI and normal BMI. Additional analyses compared OS and functional outcomes in the cohort with normal BMI and cohorts with overweight BMI (25.0-29.9) and underweight BMI (<20.0). RESULTS: Among the 166 patients included in the PSM analysis (112 men [67.1%]; mean [SD] age, 62.9 [15.4] years), obesity BMI was associated with significantly improved OS at 6 months (hazard ratio [HR], 0.54 [95% CI, 0.31-0.96]), 3 years (HR, 0.56 [95% CI, 0.38-0.83]), and 5 years (HR, 0.62 [95% CI, 0.44-0.86]) after ICI treatment, compared with patients with normal BMI. Obesity BMI was also associated with decreased risk of gastrostomy tube dependence at 6 months (odds ratio [OR], 0.41 [95% CI, 0.21-0.80]), 1 year (OR, 0.41 [95% CI, 0.21-0.78]), 3 years (OR, 0.35 [95% CI, 0.18-0.65]), and 5 years (OR, 0.34 [95% CI, 0.18-0.65]). Obesity was also associated with decreased risk for tracheostomy dependence at 1 year (OR, 0.52 [95% CI, 0.28-0.90]), 3 years (OR, 0.45 [95% CI, 0.45-0.90]), and 5 years (OR, 0.45 [95% CI, 0.45-0.90]). There were no differences in rates of dysphagia or immune-related adverse events between cohorts at any points. CONCLUSIONS AND RELEVANCE: Using population-level data for patients with HNSCC treated with ICIs, these results suggest that having obesity was associated with improved 6-month, 3-year, and 5-year OS compared with having normal BMI. Additionally, obesity was associated with decreased gastrostomy and tracheostomy tube dependence compared with normal BMI. Further investigation is required to understand the mechanism of these findings.
引用
- Mastrolonardo EV, Llerena P, Lu J, et al. Obesity and Survival After Immune Checkpoint Inhibition for Head and Neck Squamous Cell Carcinoma. JAMA Otolaryngol Head Neck Surg. 2024. PMID: 38958948. doi:10.1001/jamaoto.2024.1568
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。